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To investigate the long-term effects of efavirenz on cholesterol (TC), high-density


















































was observed and remained throughout the follow-up period. Median efavirenz
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There is evidence of a long-term and concentration-dependent beneficial effect of
efavirenz on HDL-C in HIV-infected patients.
 
Efavirenz is a non-nucleoside reverse transcriptase
inhibitor for the treatment of HIV-1-infected individ-
uals. Whereas many of the protease inhibitor (PI)-
based regimens are often associated with increased
concentrations of triglycerides (TG), total cholesterol
(TC), and low-density lipoprotein cholesterol (LDL-
C), non-nucleoside reverse transcriptase inhibitor
(NNRTI)-based regimens differ importantly, being
associated with increases in high-density lipoprotein
(HDL-C) [1–3]. However, the mechanism by which
efavirenz and nevirapine increase HDL-C is not
known.
The association between the increases in HDL-C
caused by efavirenz and the decrease in plasma HIV-1
RNA concentrations [1], the dose-dependence of the
effects of efavirenz in adipocytes [4] and the absence of
long-term follow-up studies led us to investigate the
effects of efavirenz on cholesterol, HDL-C, LDL-C and
TG and their correlation with efavirenz plasma concen-
trations over a 36-month follow-up period.












This prospective study included 34 adults, submitted to
efavirenz-containing regimens either as initial therapy
or switching from PI-containing regimens. Patients who
received PIs or lipid-lowering therapy during the follow-
up period and those with renal or hepatic failure were
excluded. All patients gave their written informed con-
sent and agreed on total adherence to treatment. The
protocol was previously approved by the Centro Hospi-
talar de Lisboa Ethics Committee. Data on fasting TG,
TC, HDL-C and LDL-C were collected at baseline
(before initiating efavirenz) and at months 3, 6, 12, 24
and 36.
Plasma samples for lipids and lipoproteins were anal-
ysed in the local clinical pathology laboratory. TC, TG
and HDL-C were assessed by standard enzymatic
assays. The concentration of LDL-C was calculated
using the Friedwald equation. To convert HDL-C, LDL-










 multiply by 0.0259. For TG the
conversion value is 0.0113.
Efavirenz plasma concentrations were analysed by a
high-performance liquid chromatography method vali-
dated by the International Interlaboratory Quality Con-
trol Program for Therapeutic Drug Monitoring in HIV
Infection (KKGT, the Netherlands). The lower limit of








































, multiply by 3.17. Plasma





The mean age and body mass index of patients studied



















Twenty-eight patients were male and 24 were naive for
any antiretroviral treatment. Mean baseline values for



























 34) in the















confidence interval (CI) 20, 63]. This effect remained

















































 0.0031, 95% CI 9, 38) months of treatment with



















) showed that their absolute
values remained higher throughout the 36-month fol-











 plus Dunnett’s test)















 (Figure 1). Pretreatment with
PIs would not contribute to large HDL-C increases after
the switch to efavirenz because the mean baseline HDL-













































 9) in those pretreated with PIs. This
beneficial increase in HDL-C was probably underesti-
mated because patients with the lowest HDL-C values
with indications to start lipid-lowering drugs were not
included.
Efavirenz plasma concentrations, monitored through-
out 36 months in a total of 110 samples, ranged from










 with a median and interquartile











inter-individual variations in plasma concentrations in











































The median (IQR) intra-individual variability was











 = 0.3441, P = 0.0003, n = 104). This
correlation was more evident (Spearman r = 0.3872,
P = 0.0005, n = 76) after 12 months of follow-up
(Figure 2A), when the bias of pretreatment experience
no longer existed. All plasma samples obtained for each
patient between months 12 and 36 were included in the
correlation analysis to avoid the bias of intra-individual
variability in HDL-C and efavirenz plasma concentra-
Figure 1 
Time course effects of antiretroviral therapy with efavirenz on high-density 
lipoprotein cholesterol (HDL-C) concentrations stratified by baseline values 
of HDL-C. Month zero corresponds to baseline values before starting 
efavirenz. , Patients with baseline concentrations of HDL-C ≥40 mg·
dL−1 (n = 9–13); , patients with baseline concentrations of HDL-C 
<40 mg·dL−1 (n = 16–21); , total (n = 25–34). Each point represents 
mean value ± SEM. *P < 0.05; **P < 0.01 Dunnett’s test comparing each 
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tions. However mean values analysis is shown in
Figure 2B (n = 34, Pearson r = 0.6258, P < 0.0001;
r2 = 0.3916; P < 0.0001).
No significant differences were found between the
LDL-C values at baseline (99 ± 6 mg ·dL−1) and the
measurements obtained, respectively, at months 3, 6, 12,
24  and  36:  118 ± 7 mg ·dL−1,  113 ± 6 mg ·dL−1,  113 ±
6 mg ·dL−1, 114 ± 7 mg ·dL−1 and 115 ± 8 mg ·dL−1.
Basal values of TC were 164 ± 8 mg ·dL−1 and signifi-
cant increases (P < 0.05, ANOVA plus Dunnett’s test)
were quantified, respectively, at months 3, 12 and 24:
193 ± 7 mg ·dL−1, 190 ± 7 mg ·dL−1 and 195 ± 12 mg ·
dL−1. A decrease in the mean values of the atherogenic
index TC/HDL-C ratio was observed at month 3 and
remained throughout the follow-up period. After month
12, an inverse correlation between the TC/HDL-C ratio
and efavirenz plasma concentrations was found (Spear-
man r = −0.3439, P = 0.0012, n = 76). This decrease
observed in the median values of the TC/HDL-C ratio
corresponded to a significant reduction in the athero-
genic index in 70% of the patients (−18% of change
from baseline, P < 0.0001). Mean efavirenz plasma con-
centrations found in the group of patients (70%) with a
decreased atherogenic index at month 12 were signifi-
cantly higher (2.36 ± 0.26 mg ·L−1, P < 0.05, unpaired t-
test) than those (1.2 ± 0.11 mg ·L−1) found in patients
(30%) in whom no reductions in TC/HDL-C were
observed.
A high inter-individual variability in TG concentra-
tions was apparent but no changes were observed in
median values of TG concentrations throughout the
study (Kruskal–Wallis test). Mean values ± SEM
quantified, respectively, at baseline and months 3, 6, 12,
24 and 36 were: 125 ± 10 mg ·dL−1, 128 ± 15 mg ·dL−1,
151 ± 25 mg ·dL−1,  131 ± 12 mg ·dL−1,  136 ± 21 mg ·
dL−1 and 136 ± 21 mg ·dL−1.
Discussion
The results are consistent with previous evidence [1–3]
of a beneficial effect of efavirenz in the protective HDL
fraction associated with an improvement in the athero-
genic index LDL-C/HDL-C or TC/HDL-C ratios. It is
shown for the first time that the effect of efavirenz
remains for at least 36 months, is significant only in
patients with baseline values of HDL-C <40 mg ·dL−1
and is related to efavirenz plasma concentrations. This
efavirenz concentration-dependent change in lipid pro-
file may suggest an efavirenz-specific beneficial effect
and explains the association between HDL-C increase
and adequate suppression of HIV-1 infection observed
in efavirenz-treated patients, which cannot be explained
only by the ‘return towards normal’ [1]. Interestingly,
it has been shown recently that efavirenz-induced
increase in HDL-C is influenced by the gene MDR-1
polymorphism  that  codes  for  the  drug  transporter
P-glycoprotein [5]. Differences in the MDR-1 gene
polymorphism have been related to the efavirenz
concentration in plasma and to the immune recovery of
CD4 lymphocyte cell counts [6]. Further studies to
clarify the clinical significance of this effect and to
elucidate mechanisms by which efavirenz increases
HDL-C during antiretroviral treatment are warranted.
However, this work allows the following inferences
regarding patient treatment to be made: the less athe-
rogenic lipid profile of efavirenz may be among the
Figure 2 
Correlation between efavirenz plasma concentrations and changes in high-
density lipoprotein cholesterol (HDL-C) from month 12 to month 36. 0% 
HDL-C variation corresponds to baseline HDL-C concentration for each 
patient before initiating the therapy with efavirenz. (A) Data corresponding 
to all the individual samples (n = 76) obtained from 34 patients 
(Spearman r = 0.3872, P = 0.0005; r2 = 0.3735; P < 0.0001). (B) Mean 
values of plasma concentrations and percentage HDL-C variation per 
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various factors to consider when selecting the most
appropriated antiretroviral regimen to treat HIV-1-
infected patients; the inclusion of statins in the thera-
peutic regimens of patients with high atherogenic index
TC/HDL-C starting antiretroviral therapy including
efavirenz could probably be avoided; and therapeutic
drug monitoring may be useful to improve the lipid
profile in these patients.
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